Compare LYEL & SPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LYEL | SPCE |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Transportation Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.1M | 331.6M |
| IPO Year | 2021 | 2017 |
| Metric | LYEL | SPCE |
|---|---|---|
| Price | $14.53 | $2.89 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 5 |
| Target Price | ★ $30.60 | $3.06 |
| AVG Volume (30 Days) | 142.6K | ★ 7.6M |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.84 |
| EPS | N/A | ★ N/A |
| Revenue | $36,000.00 | ★ $1,544,000.00 |
| Revenue This Year | N/A | $2,270.73 |
| Revenue Next Year | $8,712.13 | $880.03 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.18 | $2.13 |
| 52 Week High | $45.00 | $8.90 |
| Indicator | LYEL | SPCE |
|---|---|---|
| Relative Strength Index (RSI) | 51.10 | 46.77 |
| Support Level | $11.87 | $2.84 |
| Resistance Level | $15.63 | $3.39 |
| Average True Range (ATR) | 0.97 | 0.17 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 31.38 | 10.32 |
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.